Avila Therapeutics Inc.
By
Shirley Haley / Email the Author / START-UP November 2010, Vol. 15, No. 10
Grouped Start-Ups / Word Count: 1410 / Article # 2010900224
Executive Summary
As much as anti-hepatitis C drug telaprevir is leading the way, it has also defined what is going to be needed in a best-in-class molecule, according to the founders of Avila Therapeutics Inc. Avila's platform technology creates highly selective drugs that bond covalently to receptors, effectively silencing them and overcoming resistance mechanisms for the day or two the targets live. The Waltham, MA, biotech is the only company currently focused on covalent drugs, the company believes.
$85.00
Buy Now
For $85.00, purchase this 1410-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.